ArticleEuropean journal of rheumatology2015
Ischemia-hyperpnea test is useful to detect patients with fibromyalgia syndrome.
Article in European journal of rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo demonstrate the prevalence of neuromuscular hyperexcitability in Fibromyalgia Syndrome (FMS) by electromyography ischaemia-hyperpnea test (IHT) and its correlation with clinical and clinimetric parameters. MATERIAL AND
methodsOne hundred and forty-five FMS patients underwent IHT to evaluate neuromuscular hyperexcitability and were evaluated for pain (numeric Rating Scale and Regional Pain Scale), tenderness (tender points), disability [Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ)], quality of life (QOL) [Short Form 36 (SF36)], mood [Hospital Anxiety and Depression Scale (HADS)], sleep [numeric rating scale (NRS)], and fatigue [Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)].
resultsOf the 145 patients, 95 were tested positive by IHT, and 33 and 17 patients were negative and borderline, respectively. By comparing the three groups, IHT positive patients had lower age and lower SF36 vitality (V), social activities (SA), and mental summary index (MSI) than negative patients (p<0.05). By comparing positive versus negative patients and by comparing positive and borderline patients versus negative patients, it was found that FACIT was higher, whereas age, SF36 V, SA, mental health (MH), and MSI were lower (p<0.05).
conclusionFMS patients present a high prevalence of neuromuscular hyperexcitability, as assessed by IHT. IHT positive patients have poor QOL and higher fatigue than IHT negative patients. Thus, IHT positivity could identify FMS patients with a more severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.